Videos and Podcasts
Pharmaxic CEO Gary Phillips Presentation to NWR Virtual Health Conference
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips presented at the NWR Virtual Health Conference on Friday 1 May 2020.
Investors may view a recording of the presentation at the NWR website: https://us02web.zoom.us/webinar/register/WN_pdWZYlHJRFmjH01LYGc0NQ
Pharmaxis to progress myelofibrosis drug to Phase II following positive results
Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.
Commsec Executive Series
Pharmaxis Ltd (PXS) MD, Gary Phillips speaks with Tom Piotrowski about the company’s broad pipeline of drug candidates, large licence deal with Boehringer & upcoming Phase 2 clinical results for NASH.